- Home
- HQH vs GYRE Comparison
HQH vs GYRE Comparison
Compare HQH & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQH
- GYRE
- Stock Information
- Founded
- HQH 1986
- GYRE 2002
- Country
- HQH United States
- GYRE United States
- Employees
- HQH N/A
- GYRE N/A
- Industry
- HQH Finance Companies
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HQH Finance
- GYRE Health Care
- Exchange
- HQH Nasdaq
- GYRE Nasdaq
- Market Cap
- HQH 890.9M
- GYRE 897.1M
- IPO Year
- HQH N/A
- GYRE N/A
- Fundamental
- Price
- HQH $16.50
- GYRE $7.54
- Analyst Decision
- HQH
- GYRE Strong Buy
- Analyst Count
- HQH 0
- GYRE 1
- Target Price
- HQH N/A
- GYRE $18.00
- AVG Volume (30 Days)
- HQH 183.8K
- GYRE 94.4K
- Earning Date
- HQH 01-01-0001
- GYRE 11-12-2025
- Dividend Yield
- HQH 11.56%
- GYRE N/A
- EPS Growth
- HQH N/A
- GYRE N/A
- EPS
- HQH 1.09
- GYRE 0.02
- Revenue
- HQH N/A
- GYRE $102,189,000.00
- Revenue This Year
- HQH N/A
- GYRE $18.39
- Revenue Next Year
- HQH N/A
- GYRE $48.26
- P/E Ratio
- HQH $15.24
- GYRE $457.97
- Revenue Growth
- HQH N/A
- GYRE N/A
- 52 Week Low
- HQH $14.31
- GYRE $6.11
- 52 Week High
- HQH $17.94
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- HQH 51.04
- GYRE 46.20
- Support Level
- HQH $16.36
- GYRE $7.55
- Resistance Level
- HQH $16.85
- GYRE $8.56
- Average True Range (ATR)
- HQH 0.20
- GYRE 0.47
- MACD
- HQH -0.05
- GYRE -0.04
- Stochastic Oscillator
- HQH 29.41
- GYRE 33.77
About HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.